GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
0
c/survodutide·posted 27 days ago by u/cato_batista

MASH vs biopsy — genuinely asking which matters more

Trial Data

dual agonist. That is the whole post, but I will justify it.

Everything else people worry about in c/compounding is downstream of it. Titration speed, muscle cramps, the endless dose arguments — most of it resolves if you sort dual agonist out first, and almost nobody does.

I say this having got it wrong for 15 months. My triglycerides was the thing that eventually made me pay attention, which is a stupid way to learn a lesson that was in the sidebar the whole time.

0 up / 0 down48% upvoted8 commentsid 17s8s72 Jul 2026

8 comments

8 in this archive, depth 5

best — the order this archive was captured in

u/nadia_bakker-21 points·26 days ago

Yeah, glucagon co-agonism is genuinely different.

replysharereportpermalink
u/titration_marshalmod · c/semaglutide1 point·26 days ago

Which trial arm?

replysharereportpermalink
u/jarno_adeyemi1 point·25 days ago

Disagree but this is the good kind of wrong — it is specific enough to be checked.

replysharereportpermalink
u/ismael_nwosu1 point·26 days ago

Which trial arm?

replysharereportpermalink
u/cato_batistaOP1 point·26 days ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/endotoxin_elliemicro1 point·25 days ago

glucagon injection is a different vector than GLP-1

replysharereportpermalink
u/sofia_danquah1 point·25 days ago

glucagon injection is a different vector than GLP-1

Yes, exactly this, and it is the bit that took me 69 weeks to accept.

replysharereportpermalink
u/cold_chromatogram_only1 point·25 days ago

MASH claims need the trial and the biopsy endpoint

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →